Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04209855
Registration number
NCT04209855
Ethics application status
Date submitted
17/12/2019
Date registered
24/12/2019
Date last updated
6/03/2023
Titles & IDs
Public title
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Query!
Scientific title
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Query!
Secondary ID [1]
0
0
2019-003509-80
Query!
Secondary ID [2]
0
0
IMGN853-0416
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
MIRASOL
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Epithelial Ovarian Cancer
0
0
Query!
Peritoneal Cancer
0
0
Query!
Fallopian Tube Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Ovarian and primary peritoneal
Query!
Cancer
0
0
0
0
Query!
Womb (Uterine or endometrial cancer)
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Mirvetuximab Soravtansine
Treatment: Drugs - Paclitaxel
Treatment: Drugs - Topotecan
Treatment: Drugs - Pegylated liposomal doxorubicin
Experimental: mirvetuximab soravtansine (MIRV; IMGN853) - MIRV 6 mg/kg adjusted ideal body weight (AIBW) every 3 weeks (Q3W)
Active Comparator: Investigator's choice of chemotherapy - Paclitaxel (Pac; 80 mg/m2) administered once per week (QW) within a 4-week cycle
Pegylated liposomal doxorubicin (PLD; 40 mg/m2) administered every 4 weeks (Q4W)
Topotecan (Topo; 4 mg/m2) administered either on Days 1, 8, and 15 every 4 weeks or for 5 consecutive days (1.25 mg/m2 Days 1-5) every 3 weeks (Q3W)
Treatment: Drugs: Mirvetuximab Soravtansine
Mirvetuximab soravtansine is an antibody drug conjugate designed to target folate receptor a (FRa). It consists of the humanized anti-FRa mAb M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4.
Treatment: Drugs: Paclitaxel
Paclitaxel is a taxane that can stabilize microtubules to inhibit cell division. It was approved for treatment of recurrent epithelial ovarian cancer.
Treatment: Drugs: Topotecan
Topotecan induces irreversible DNA damage. It inhibits topoisomerase 1, leading to both single and double strand DNA break that eventually promote apoptosis. Topotecan was approved for treatment of epithelial ovarian cancer after failure of initial or subsequent chemotherapy.
Treatment: Drugs: Pegylated liposomal doxorubicin
Pegylated liposomal doxorubicin is a standard chemotherapy regimen used for treating platinum-resistant ovarian cancer. The active component doxorubicin is an anthracycline that intercalates DNA, leading to inhibition of replication and subsequently, the inhibition of proper cell division.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression-free survival (PFS)
Query!
Assessment method [1]
0
0
The time from date of randomization until Investigator-assessed progressive disease or death, whichever occurs first.
Query!
Timepoint [1]
0
0
Up to 2 years
Query!
Secondary outcome [1]
0
0
Safety and tolerability
Query!
Assessment method [1]
0
0
Adverse events (AEs) will be evaluated according to the NCI CTCAE v5.0. AEs will be coded using the latest Medical Dictionary for Regulatory Activities (MedDRA) version and summarized per system organ class (SOC) and preferred term (PT).
Query!
Timepoint [1]
0
0
Up to 2 years
Query!
Secondary outcome [2]
0
0
Objective Response Rate (ORR)
Query!
Assessment method [2]
0
0
Objective response includes best response of complete response (CR) or partial response (PR).
Query!
Timepoint [2]
0
0
Up to 2 years
Query!
Secondary outcome [3]
0
0
Overall survival
Query!
Assessment method [3]
0
0
The time from date of randomization until the date of death
Query!
Timepoint [3]
0
0
Up to 2 years
Query!
Secondary outcome [4]
0
0
Primary patient-reported outcomes
Query!
Assessment method [4]
0
0
The number of patients achieving at least 15 point absolute improvement at Week 8 or Week 9 in the abdominal/GI scale of the European Organization for Research and Treatment of Cancer (EORTC) ovarian cancer specific quality of life questionnaire (QLQ-OV28). A higher score represents a better quality of life.
Query!
Timepoint [4]
0
0
Up to 2 years
Query!
Secondary outcome [5]
0
0
Duration of response (DOR)
Query!
Assessment method [5]
0
0
The time from initial response until Investigator-assessed progressive disease for all patients who achieve a confirmed objective response
Query!
Timepoint [5]
0
0
Up to 2 years
Query!
Secondary outcome [6]
0
0
CA-125 response
Query!
Assessment method [6]
0
0
Serum CA-125 response determined using the GCIG criteria
Query!
Timepoint [6]
0
0
Up to 2 years
Query!
Secondary outcome [7]
0
0
Progression-free survival 2 (PFS 2)
Query!
Assessment method [7]
0
0
The time from date of randomization until second disease progression or death whichever occurs first. Results will be summarized by arm
Query!
Timepoint [7]
0
0
Up to 2 years
Query!
Eligibility
Key inclusion criteria
1. Female patients = 18 years of age
2. Patients must have a confirmed diagnosis of high-grade serious epithelial ovarian
cancer, primary peritoneal cancer, or fallopian tube cancer
3. Patients must have platinum-resistant disease:
1. Patients who have only had 1 line of platinum based therapy must have received at
least 4 cycles of platinum, must have had a response (CR or PR) and then
progressed between >3 months and = 6 months after the date of the last dose of
platinum
2. Patients who have received 2 or 3 lines of platinum therapy must have progressed
on or within 6 months after the date of the last dose of platinum Note:
Progression should be calculated from the date of the last administered dose of
platinum therapy to the date of the radiographic imaging showing progression.
Note: Patients who are platinum-refractory during front-line treatment are
excluded
4. Patients must have progressed radiographically on or after their most recent line of
therapy
5. Patients must be willing to provide an archival tumor tissue block or slides, or
undergo procedure to obtain a new biopsy using a low risk, medically routine procedure
for IHC confirmation of FRa positivity
6. Patient's tumor must be positive for FRa expression as defined by the Ventana FOLR1
(FOLR-2.1) CDx assay
7. Patients must have at least one lesion that meets the definition of measurable disease
by RECIST v1.1 (radiologically measured by the Investigator)
8. Patients must have received at least 1 but no more than 3 prior systemic lines of
anticancer therapy, and for whom single-agent therapy is appropriate as the next line
of treatment:
1. Adjuvant ± neoadjuvant considered one line of therapy
2. Maintenance therapy (eg, bevacizumab, PARP inhibitors) will be considered as part
of the preceding line of therapy (ie, not counted independently)
3. Therapy changed due to toxicity in the absence of progression will be considered
as part of the same line (ie, not counted independently)
4. Hormonal therapy will be counted as a separate line of therapy unless it was
given as maintenance
9. Patient must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS)
of 0 or 1
10. Time from prior therapy:
1. Systemic antineoplastic therapy (5 half-lives or 4 weeks, whichever is shorter)
2. Focal radiation completed at least 2 weeks prior to first dose of study drug
11. Patients must have stabilized or recovered (Grade 1 or baseline) from all prior
therapy-related toxicities
12. Major surgery must be completed at least 4 weeks prior to first dose and have
recovered or stabilized from the side effects of prior surgery
13. Patients must have adequate hematologic, liver and kidney functions defined as:
1. Absolute neutrophil count (ANC) = 1.5 x 10^9/L (1,500/µL) without G-CSF in the
prior 10 days or long-acting WBC growth factors in the prior 20 days
2. Platelet count = 100 x 10^9/L (100,000/µL) without platelet transfusion in the
prior 10 days
3. Hemoglobin = 9.0 g/dL without packed red blood cell (PRBC) transfusion in the
prior 21 days
4. Serum creatinine = 1.5 x upper limit of normal (ULN)
5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 3.0 x ULN
6. Serum bilirubin = 1.5 x ULN (patients with documented diagnosis of Gilbert
syndrome are eligible if total bilirubin < 3.0 x ULN
7. Serum albumin = 2 g/dL
14. Patients or their legally authorized representative must be willing and able to sign
the informed consent form (ICF) and to adhere to the protocol requirements
15. Women of childbearing potential (WCBP) must agree to use highly effective
contraceptive method(s) (as defined in Section 5.9.6 in the protocol) while on study
drug and for at least 3 months after the last dose of MIRV or at least 6 months after
the last dose of paclitaxel, pegylated liposomal doxorubicin, or topotecan
16. WCBP must have a negative pregnancy test within 4 days prior to the first dose of
study drug
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Patients with endometrioid, clear cell, mucinous, or sarcomatous histology, mixed
tumors containing any of the above histologies, or low-grade or borderline ovarian
tumor
2. Patients with primary platinum-refractory disease, defined as disease that did not
respond to (CR or PR) or has progressed within 3 months of the last dose of first line
platinum-containing chemotherapy
3. Patients with prior wide-field radiotherapy (RT) affecting at least 20% of the bone
marrow
4. Patients with > Grade 1 peripheral neuropathy per CTCAE v5.0
5. Patients with active or chronic corneal disorders, history of corneal transplantation,
or active ocular conditions requiring ongoing treatment/monitoring such as
uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal
injections, active diabetic retinopathy with macular edema, macular degeneration,
presence of papilledema, and /or monocular vision
6. Patients with serious concurrent illness or clinically relevant active infection,
including, but not limited to the following:
1. Active hepatitis B or C infection (whether or not on active antiviral therapy)
2. HIV infection
3. Active cytomegalovirus infection
4. Any other concurrent infectious disease requiring IV antibiotics within 2 weeks
before starting study drug Note: Testing at screening is not required for the
above infections unless clinically indicated
7. Patients with history of multiple sclerosis or other demyelinating disease and/or
Lambert-Eaton syndrome (paraneoplastic syndrome)
8. Patients with clinically significant cardiac disease including, but not limited to,
any one of the following:
1. Myocardial infarction = 6 months prior to first dose
2. Unstable angina pectoris
3. Uncontrolled congestive heart failure (New York Heart Association > class II)
4. Uncontrolled = Grade 3 hypertension (per CTCAE)
5. Uncontrolled cardiac arrhythmias
9. Patients assigned to PLD stratum only: Left ventricular ejection fraction (LVEF) below
the institutional limit of normal as measured by echocardiography (ECHO) or multigated
acquisition (MUGA) scan
10. Patients with a history of hemorrhagic or ischemic stroke within six months prior to
randomization
11. Patients with a history of cirrhotic liver disease (Child-Pugh Class B or C)
12. Patients with a previous clinical diagnosis of non-infectious interstitial lung
disease (ILD), including noninfectious pneumonitis
13. Patients with required use of folate-containing supplements (eg, folate deficiency)
14. Patients with prior hypersensitivity to monoclonal antibodies
15. Women who are pregnant or lactating
16. Patients with prior treatment with MIRV or other FRa-targeting agents
17. Patients with untreated or symptomatic central nervous system (CNS) metastases
18. Patients with a history of other malignancy within 3 years prior to randomization.
Note: does not include tumors with a negligible risk for metastasis or death (eg,
adequately controlled basal-cell carcinoma or squamous-cell carcinoma of the skin, or
carcinoma in situ of the cervix or breast
19. Prior known hypersensitivity reactions to study drugs and/or any of their excipients
20. People who are detained through a court or administrative decision, receiving
psychiatric care against their will, adults who are the subject of a legal protection
order (under tutorship/curatorship), people who are unable to express their consent,
and people who are subject to a legal guardianship order
21. Simultaneous participation in another research study, in countries or localities where
this is the health authority guidance
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
31/12/2019
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/04/2024
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
453
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
Newcastle Private Hospital - New Lambton Heights
Query!
Recruitment hospital [2]
0
0
Prince of Wales Hospital - Randwick
Query!
Recruitment hospital [3]
0
0
Monash Health - Clayton
Query!
Recruitment hospital [4]
0
0
Oncology Clinics Victoria (OCV) - Cabrini Malvern Hospital Location - Malvern
Query!
Recruitment hospital [5]
0
0
Royal North Shore Hospital - Saint Leonards
Query!
Recruitment hospital [6]
0
0
Burnside War Memorial Hospital - The Brian Fricker Oncology Centre - Toorak Gardens
Query!
Recruitment postcode(s) [1]
0
0
2305 - New Lambton Heights
Query!
Recruitment postcode(s) [2]
0
0
2031 - Randwick
Query!
Recruitment postcode(s) [3]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [4]
0
0
3144 - Malvern
Query!
Recruitment postcode(s) [5]
0
0
2065 - Saint Leonards
Query!
Recruitment postcode(s) [6]
0
0
5065 - Toorak Gardens
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Alaska
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arizona
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Colorado
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Connecticut
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Florida
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Georgia
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Hawaii
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Illinois
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Indiana
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Kansas
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Kentucky
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Louisiana
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Maryland
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Massachusetts
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Michigan
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Minnesota
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Missouri
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Montana
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Nevada
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
New Jersey
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
New York
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
North Carolina
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Ohio
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Oklahoma
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Oregon
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Pennsylvania
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Rhode Island
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Tennessee
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
Texas
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
Virginia
Query!
Country [33]
0
0
United States of America
Query!
State/province [33]
0
0
Washington
Query!
Country [34]
0
0
United States of America
Query!
State/province [34]
0
0
West Virginia
Query!
Country [35]
0
0
Belgium
Query!
State/province [35]
0
0
Aalst
Query!
Country [36]
0
0
Belgium
Query!
State/province [36]
0
0
Brasschaat
Query!
Country [37]
0
0
Belgium
Query!
State/province [37]
0
0
Edegem
Query!
Country [38]
0
0
Belgium
Query!
State/province [38]
0
0
Gent
Query!
Country [39]
0
0
Belgium
Query!
State/province [39]
0
0
Leuven
Query!
Country [40]
0
0
Bulgaria
Query!
State/province [40]
0
0
Pleven
Query!
Country [41]
0
0
Bulgaria
Query!
State/province [41]
0
0
Sofia
Query!
Country [42]
0
0
Canada
Query!
State/province [42]
0
0
Alberta
Query!
Country [43]
0
0
Canada
Query!
State/province [43]
0
0
Ontario
Query!
Country [44]
0
0
Canada
Query!
State/province [44]
0
0
Quebec
Query!
Country [45]
0
0
China
Query!
State/province [45]
0
0
Anhui
Query!
Country [46]
0
0
China
Query!
State/province [46]
0
0
Fujian
Query!
Country [47]
0
0
China
Query!
State/province [47]
0
0
Guangdong
Query!
Country [48]
0
0
China
Query!
State/province [48]
0
0
Hubei
Query!
Country [49]
0
0
China
Query!
State/province [49]
0
0
Jiangsu
Query!
Country [50]
0
0
China
Query!
State/province [50]
0
0
Jilin
Query!
Country [51]
0
0
China
Query!
State/province [51]
0
0
Liaoning
Query!
Country [52]
0
0
China
Query!
State/province [52]
0
0
Shanxi
Query!
Country [53]
0
0
China
Query!
State/province [53]
0
0
Beijing
Query!
Country [54]
0
0
China
Query!
State/province [54]
0
0
Shanghai
Query!
Country [55]
0
0
China
Query!
State/province [55]
0
0
Tianjin
Query!
Country [56]
0
0
Czechia
Query!
State/province [56]
0
0
Ostrava
Query!
Country [57]
0
0
Czechia
Query!
State/province [57]
0
0
Praha 2
Query!
Country [58]
0
0
Czechia
Query!
State/province [58]
0
0
Zlín
Query!
Country [59]
0
0
France
Query!
State/province [59]
0
0
Cedex 9
Query!
Country [60]
0
0
France
Query!
State/province [60]
0
0
Cedex B.P 307
Query!
Country [61]
0
0
France
Query!
State/province [61]
0
0
Cedex
Query!
Country [62]
0
0
France
Query!
State/province [62]
0
0
Besançon Cedex
Query!
Country [63]
0
0
France
Query!
State/province [63]
0
0
Bordeaux Cedex
Query!
Country [64]
0
0
France
Query!
State/province [64]
0
0
Lyon Cedex
Query!
Country [65]
0
0
France
Query!
State/province [65]
0
0
Marseille
Query!
Country [66]
0
0
France
Query!
State/province [66]
0
0
Paris
Query!
Country [67]
0
0
France
Query!
State/province [67]
0
0
Pierre-Bénite
Query!
Country [68]
0
0
France
Query!
State/province [68]
0
0
Plerin
Query!
Country [69]
0
0
France
Query!
State/province [69]
0
0
Saint Cloud
Query!
Country [70]
0
0
France
Query!
State/province [70]
0
0
St. Herblain CEDEX
Query!
Country [71]
0
0
France
Query!
State/province [71]
0
0
Vandoeuvre les Nancy_ Cedex
Query!
Country [72]
0
0
France
Query!
State/province [72]
0
0
Villejuif Cedex
Query!
Country [73]
0
0
Germany
Query!
State/province [73]
0
0
Baden-Württemberg
Query!
Country [74]
0
0
Germany
Query!
State/province [74]
0
0
Niedersachsen
Query!
Country [75]
0
0
Germany
Query!
State/province [75]
0
0
Saxony
Query!
Country [76]
0
0
Germany
Query!
State/province [76]
0
0
Bonn
Query!
Country [77]
0
0
Germany
Query!
State/province [77]
0
0
Dessau
Query!
Country [78]
0
0
Germany
Query!
State/province [78]
0
0
Dortmund
Query!
Country [79]
0
0
Germany
Query!
State/province [79]
0
0
Freiburg
Query!
Country [80]
0
0
Germany
Query!
State/province [80]
0
0
Hamburg
Query!
Country [81]
0
0
Israel
Query!
State/province [81]
0
0
Holon
Query!
Country [82]
0
0
Israel
Query!
State/province [82]
0
0
Jerusalem
Query!
Country [83]
0
0
Israel
Query!
State/province [83]
0
0
Kfar Saba
Query!
Country [84]
0
0
Israel
Query!
State/province [84]
0
0
Ramat Gan
Query!
Country [85]
0
0
Israel
Query!
State/province [85]
0
0
Rehovot
Query!
Country [86]
0
0
Israel
Query!
State/province [86]
0
0
Safed
Query!
Country [87]
0
0
Italy
Query!
State/province [87]
0
0
PD
Query!
Country [88]
0
0
Italy
Query!
State/province [88]
0
0
Brescia
Query!
Country [89]
0
0
Italy
Query!
State/province [89]
0
0
Lecco
Query!
Country [90]
0
0
Italy
Query!
State/province [90]
0
0
Milan
Query!
Country [91]
0
0
Italy
Query!
State/province [91]
0
0
Naples
Query!
Country [92]
0
0
Italy
Query!
State/province [92]
0
0
Reggio Emilia
Query!
Country [93]
0
0
Italy
Query!
State/province [93]
0
0
Rome
Query!
Country [94]
0
0
Italy
Query!
State/province [94]
0
0
Torino
Query!
Country [95]
0
0
Korea, Republic of
Query!
State/province [95]
0
0
Gyeonggi-do
Query!
Country [96]
0
0
Korea, Republic of
Query!
State/province [96]
0
0
Seongnam-si
Query!
Country [97]
0
0
Korea, Republic of
Query!
State/province [97]
0
0
Seoul
Query!
Country [98]
0
0
Netherlands
Query!
State/province [98]
0
0
Amsterdam
Query!
Country [99]
0
0
Netherlands
Query!
State/province [99]
0
0
Maastricht
Query!
Country [100]
0
0
Netherlands
Query!
State/province [100]
0
0
Nijmegen
Query!
Country [101]
0
0
Netherlands
Query!
State/province [101]
0
0
Rotterdam
Query!
Country [102]
0
0
Poland
Query!
State/province [102]
0
0
Gdansk
Query!
Country [103]
0
0
Poland
Query!
State/province [103]
0
0
Lublin
Query!
Country [104]
0
0
Poland
Query!
State/province [104]
0
0
Olsztyn
Query!
Country [105]
0
0
Poland
Query!
State/province [105]
0
0
Poznan
Query!
Country [106]
0
0
Poland
Query!
State/province [106]
0
0
Warszawa
Query!
Country [107]
0
0
Portugal
Query!
State/province [107]
0
0
Lisbon
Query!
Country [108]
0
0
Portugal
Query!
State/province [108]
0
0
Loures
Query!
Country [109]
0
0
Russian Federation
Query!
State/province [109]
0
0
Omsk Oblast
Query!
Country [110]
0
0
Russian Federation
Query!
State/province [110]
0
0
Moscow
Query!
Country [111]
0
0
Russian Federation
Query!
State/province [111]
0
0
St-Petersburg
Query!
Country [112]
0
0
Russian Federation
Query!
State/province [112]
0
0
Ufa
Query!
Country [113]
0
0
Serbia
Query!
State/province [113]
0
0
Belgrade
Query!
Country [114]
0
0
Serbia
Query!
State/province [114]
0
0
Kragujevac
Query!
Country [115]
0
0
Serbia
Query!
State/province [115]
0
0
Sremska Kamenica
Query!
Country [116]
0
0
Spain
Query!
State/province [116]
0
0
A Coruña
Query!
Country [117]
0
0
Spain
Query!
State/province [117]
0
0
Andalucia
Query!
Country [118]
0
0
Spain
Query!
State/province [118]
0
0
Madrid
Query!
Country [119]
0
0
Spain
Query!
State/province [119]
0
0
Badalona
Query!
Country [120]
0
0
Spain
Query!
State/province [120]
0
0
Caceres
Query!
Country [121]
0
0
Spain
Query!
State/province [121]
0
0
Castelló
Query!
Country [122]
0
0
Spain
Query!
State/province [122]
0
0
Murcia
Query!
Country [123]
0
0
Spain
Query!
State/province [123]
0
0
Sabadell
Query!
Country [124]
0
0
Spain
Query!
State/province [124]
0
0
Sevilla
Query!
Country [125]
0
0
Spain
Query!
State/province [125]
0
0
Valencia
Query!
Country [126]
0
0
Spain
Query!
State/province [126]
0
0
Zaragoza
Query!
Country [127]
0
0
Taiwan
Query!
State/province [127]
0
0
New Taipei City
Query!
Country [128]
0
0
Taiwan
Query!
State/province [128]
0
0
Taipei City
Query!
Country [129]
0
0
Ukraine
Query!
State/province [129]
0
0
Chernihiv Region
Query!
Country [130]
0
0
Ukraine
Query!
State/province [130]
0
0
Kharkiv Region
Query!
Country [131]
0
0
Ukraine
Query!
State/province [131]
0
0
Khmelnytskyi Region
Query!
Country [132]
0
0
Ukraine
Query!
State/province [132]
0
0
Cherkasy
Query!
Country [133]
0
0
Ukraine
Query!
State/province [133]
0
0
Ivano-Frankivsk
Query!
Country [134]
0
0
United Kingdom
Query!
State/province [134]
0
0
Cambridgeshire
Query!
Country [135]
0
0
United Kingdom
Query!
State/province [135]
0
0
Devon
Query!
Country [136]
0
0
United Kingdom
Query!
State/province [136]
0
0
Coventry
Query!
Country [137]
0
0
United Kingdom
Query!
State/province [137]
0
0
Glasgow
Query!
Country [138]
0
0
United Kingdom
Query!
State/province [138]
0
0
London
Query!
Country [139]
0
0
United Kingdom
Query!
State/province [139]
0
0
Manchester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
ImmunoGen, Inc.
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
Gynecologic Oncology Group
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Other collaborator category [2]
0
0
Other
Query!
Name [2]
0
0
European Network of Gynaecological Oncological Trial Groups (ENGOT)
Query!
Address [2]
0
0
Query!
Country [2]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This Phase 3 study is designed to compare the efficacy and safety of mirvetuximab
soravtansine vs. investigator's choice chemotherapy in patients with platinum-resistant
high-grade epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, whose
tumors express a high-level of FRa. Patients will be, in the opinion of the Investigator,
appropriate for single-agent therapy for their next line of therapy. Folate receptor alpha
(FRa) positivity will be defined by the Ventana FOLR1 (FOLR1-2.1) CDx assay.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04209855
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Michael Method, MPH, MBA
Query!
Address
0
0
ImmunoGen, Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04209855
Download to PDF